MDS 2023 | Pre-MDS states: novel therapeutic approaches, and determining appropriate trial endpoints
Klaus Metzeler, MD, University of Leipzig Medical Center, Leipzig, Germany, discusses treatment options for patients with the pre-myelodysplastic syndrome (pre-MDS) states of clonal hematopoiesis (CH) and clonal cytopenia. Dr Metzeler explains that ongoing trials are investigating novel therapeutic approaches to treat patients with these conditions. Dr Metzeler offers a description of the two broad categories of these therapeutics, which are genotype-specific agents and agents targeting the CH-associated microenvironment. To conclude, Dr Metzeler comments on the importance of designing relevant endpoints for trials investigating pre-MDS therapies, particularly with regard to the timing of interventions such as transfusion. This interview took place at the 17th International Congress on Myelodysplastic Syndromes 2023 (MDS 2023) held in Marseille, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
